|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,180.10 INR | +1.06% |
|
-4.48% | -0.25% |
| Capitalization | 685B 7.59B 6.52B 6.07B 5.64B 10.53B 11.36B 69.74B 27.44B 328B 28.47B 27.89B 1,201B | P/E ratio 2026 * |
19x | P/E ratio 2027 * | 15.6x |
|---|---|---|---|---|---|
| Enterprise value | 655B 7.25B 6.22B 5.79B 5.39B 10.06B 10.85B 66.62B 26.21B 313B 27.2B 26.64B 1,148B | EV / Sales 2026 * |
1.97x | EV / Sales 2027 * | 1.72x |
| Free-Float |
45.16% | Yield 2026 * |
0.41% | Yield 2027 * | 0.43% |
Last Transcript: Aurobindo Pharma
| 1 day | +1.06% | ||
| 1 week | -4.48% | ||
| Current month | -0.25% | ||
| 1 month | -1.26% | ||
| 3 months | +4.92% | ||
| 6 months | +3.64% | ||
| Current year | -0.25% |
| 1 week | 1,154.4 |  | 1,211.4 |
| 1 month | 1,154.4 | | 1,270.8 |
| Current year | 1,154.4 | | 1,270.8 |
| 1 year | 1,010 | | 1,278.6 |
| 3 years | 397.2 | | 1,592 |
| 5 years | 397.2 | | 1,592 |
| 10 years | 288.85 | | 1,592 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 68 | 2021-12-31 | |
| Director of Finance/CFO | - | 2014-06-30 | |
B. Adi Reddy
CMP | Compliance Officer | - | 2016-05-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 68 | 2009-11-02 | |
| Director/Board Member | 68 | 1988-12-31 | |
| Director/Board Member | 66 | 2006-09-17 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +5.31% | 0.22% | 44 M€ | |
| +5.04% | 0.12% | 11 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +1.06% | -4.48% | +0.48% | +171.19% | 7.59B | |
| -4.71% | -5.82% | +36.87% | +185.69% | 961B | |
| -1.07% | +5.26% | +49.39% | +25.65% | 527B | |
| -2.50% | -2.75% | +27.20% | +42.62% | 392B | |
| -0.19% | +1.50% | +29.56% | +16.94% | 368B | |
| -2.26% | -0.62% | +32.31% | +20.66% | 299B | |
| -1.34% | +0.97% | +26.81% | +33.22% | 279B | |
| -1.87% | -1.96% | +8.72% | -1.48% | 276B | |
| -3.08% | -1.11% | -39.46% | -23.11% | 262B | |
| -1.07% | -1.01% | +21.50% | +21.28% | 177B | |
| Average | -1.72% | -0.07% | +19.34% | +49.27% | 354.83B | |
| Weighted average by Cap. | -2.47% | +0.03% | +27.05% | +64.52% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 332B 3.68B 3.16B 2.94B 2.74B 5.11B 5.51B 33.82B 13.3B 159B 13.81B 13.52B 583B | 368B 4.08B 3.5B 3.26B 3.03B 5.66B 6.1B 37.45B 14.73B 176B 15.29B 14.98B 645B |
| Net income | 36.4B 403M 346M 322M 300M 559M 603M 3.7B 1.46B 17.41B 1.51B 1.48B 63.81B | 44.01B 488M 418M 390M 362M 676M 729M 4.48B 1.76B 21.05B 1.83B 1.79B 77.15B |
| Net Debt | -30.64B -339M -291M -271M -252M -471M -508M -3.12B -1.23B -14.66B -1.27B -1.25B -53.7B | -52.61B -583M -500M -466M -433M -809M -872M -5.35B -2.11B -25.17B -2.19B -2.14B -92.22B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-01-14 | 1,180.10 ₹ | +1.06% | 726,275 |
| 26-01-13 | 1,167.70 ₹ | -0.44% | 854,954 |
| 26-01-12 | 1,172.90 ₹ | -2.15% | 689,082 |
| 26-01-09 | 1,198.70 ₹ | -0.61% | 889,120 |
| 26-01-08 | 1,206.10 ₹ | -2.37% | 879,596 |
Delayed Quote NSE India S.E., January 14, 2026 at 07:40 am EST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- AUROPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
